The Effect of Bethanechol on Tracheobronchomalacia

Launched by ARKANSAS CHILDREN'S HOSPITAL RESEARCH INSTITUTE · Mar 18, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called bethanechol on infants diagnosed with a condition known as tracheobronchomalacia, which is a weakening of the airways that can make it difficult for them to breathe. The main goal of the study is to see if taking bethanechol can help reduce the effort these infants need to make when breathing, specifically looking for at least a 20% improvement in a measured breathing effort after starting the medication.

To be eligible for this trial, infants need to have a confirmed diagnosis of tracheobronchomalacia, showing significant airway collapse during breathing tests. They should be receiving care in a specialized Neonatal Intensive Care Unit. Infants who do not meet these criteria, such as those with less severe airway collapse or other specific airway issues, will not be included. Participants in the trial will be monitored to see how their breathing improves with the treatment. This study is currently looking for participants, so families interested in this option should speak with their medical team for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Infants with a diagnosis of tracheobronchomalacia by dynamic computed tomography and showing \> 50% cross-sectional diameter collapse at 40 to 60 post menstrual age and for whom will be treatment with bethanechol in level IV center Neonatal Intensive Care Unit.
• Exclusion Criteria:
• • Infants with diagnosis of tracheobronchomalacia by dynamic computed tomography with \< 50% cross-sectional diameter collapse at 40 to 60 post menstrual age, or infants in which the medical team has not made the decision to start bethanechol.
• • Patients with fixed tracheomalacia or bronchomalacia due to external compression of airways.